menu
    • menu
    [{"orgOrder":0,"company":"Brain Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GREECE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Midazolam Maleate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Brain Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Inhalation","sponsorNew":"Brain Therapeutics \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Brain Therapeutics \/ Neuraxpharm"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Midazolam Maleate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Inhalation","sponsorNew":"Takeda Pharmaceutical \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Midazolam Maleate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Inhalation","sponsorNew":"Neuraxpharm \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Permira","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Midazolam Maleate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Neuraxpharm \/ Permira","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Permira"}]

    Find Clinical Drug Pipeline Developments & Deals for Midazolam Maleate

    Menu

    Midazolam Maleate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Brain Therapeutics

                            Greece arrow
                            German Wound Congress
                            Not Confirmed

                            Brain Therapeutics

                            Greece arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm Expands Its Business in Southeast Europe

                            Details : Having acquired Brain Therapeutics, Neuraxpharm is now able to bring new products to the Greek market including the market-leading product for emergency treatment of children and adolescents with epilepsy, Buccolam®, will be among the products to be off...

                            Product Name : Buccolam

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 03, 2022

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neuraxpharm

                            Spain arrow
                            German Wound Congress
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neuraxpharm Launches First Product in Japan

                            Details : Buccolam (oromucosal midazolam), value-added buccal midazolam indicated for emergency treatment of children and adolescents from 3 months to 18 years with epilepsy suffering from prolonged acute convulsive seizures.

                            Product Name : Buccolam

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 01, 2021

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neuraxpharm

                            Spain arrow
                            German Wound Congress
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Permira

                            Deal Size : $1,880.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Permira Funds to Acquire Leading European CNS Specialty Pharmaceutical Company Neuraxpharm

                            Details : The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expa...

                            Product Name : Buccolam

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 22, 2020

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Permira

                            Deal Size : $1,880.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Takeda Pharmaceutical

                            Japan arrow
                            German Wound Congress
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm Acquires Market-Leading Buccolam® For Emergency Treatment of Epileptic Children

                            Details : Buccolam® (Midazolam), fits perfectly within Neuraxpharm’s portfolio, strengthening its position as the European CNS specialist in several European countries, and offers the opportunity to expand the commercial footprint, including into the Nordics an...

                            Product Name : Buccolam

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 14, 2020

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth